Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal diseases. This cancer presents aggressive phenotypes, such as progression, invasion, drug resistance, metastasis, and recurrence. Moreover, patients with PDAC do not present specific symptoms, and most of the time, the disease is diagnosed at a later stage with metastases [1]. Therefore, screening tools to assist early-stage PDAC detection and to histologically identify precursor cells and tissues are needed.

In PDAC, successive gene mutations and protein expression changes occur at various phases of tumorigenesis, including precursor conditions. Three premalignant precursor lesions of PDAC with different histological subtypes have been identified and are termed pancreatic intraepithelial neoplasia (PanIN), intraductal pancreatic mucinous neoplasia (IPMN), and mucinous cystic neoplasia (MCN) [1]. PanIN is considered the most common precursor of PDAC, along with KRAS mutations, which occur in more than 90% of patients with PDAC and can be detected in the early PanIN stage [1–3].

Chronic pancreatitis is also considered a cause of pancreatic cancer [4] and a risk factor for PDAC, in addition to cigarette smoking, heavy alcohol intake, and diabetes mellitus [5]. Chronic pancreatitis is commonly defined as continual inflammation of the pancreas that
PRDM14 overexpression in chronic pancreatitis

C. Moriya et al.

does not heal or improve, characterized by irreversible morphologic changes, such as the replacement of pancreatic acinar cells by fibrotic tissue. In contrast, acute pancreatitis, a sudden inflammation of pancreas that may result in life-threatening complications, generally recovers completely and is not a risk factor for PDAC. The relation between cancer and chronic inflammation has been also suggested in other tissues. For example, hepatocellular carcinoma generally develops following chronic hepatitis with expression of hepatic progenitor cell markers, and the cancer stem cell phenotypes of hepatocellular carcinoma are inhibited by pharmacological inhibition of interleukin-6 signaling, which is increased in chronic hepatitis [6,7].

PRDM14 is a member of the PR domain-containing family and a transcription regulator required for maintaining pluripotency in embryonic stem cells [8]. PRDM14 is reported to be overexpressed in several cancers and related to cancer phenotypes [9–11]. Recently, we reported that PRDM14 is overexpressed in PDAC tissues, compared to normal pancreatic tissues, and silencing the expression decreased cancer stem-like phenotypes including side population (SP) cells, tumor formation, and liver metastasis [12]. Interestingly, PRDM14 was also overexpressed in PDAC adjacent tissues, which were histologically non-neoplastic areas around the tumor, implying PRDM14 overexpression occurs at tumor origin and contributes to tumorigenesis [12]. However, whether PRDM14 overexpression occurs prior to PDAC remains unknown.

In this study, we assessed the expression levels of PRDM14 in several pathological tissues, including PanIN and chronic pancreatitis. PRDM14 was overexpressed in chronic pancreatitis tissues as well as PDAC and cancer adjacent tissues. To estimate the relationship between PRDM14 overexpression and inflammation, we performed experiments using a cerulein-induced chronic pancreatitis mouse model. Cerulein is an analogue of cholecystokinin, which shows high serum levels in patients with acute pancreatitis and is used for pancreatitis induction in a rodent model. Cerulein induces phenotypes of pancreatitis, such as amylase release, acinar cell death, and infiltration of inflammatory cells into the pancreas [13–16]. We also assessed PRDM14 expression in cerulein-treated pancreatic cancer cell lines.

Materials and methods

Immunohistochemistry

Tissue microarray (TMA) slides containing pancreatitis and pancreas intraepithelial neoplasia were purchased from Biomax (Rockville, MD, USA; PA811, PA485, BIC14011). Mouse tissues were formalin-fixed, paraffin-embedded (FFPE), and sliced. IHC was performed as described previously [12]. We used the following primary antibodies: human PRDM14 (ab187881) from Abcam Inc. (Cambridge, MA, USA) and mouse PRDM14 (#38965) from Signalway antibody (Pearland, TX, USA). The slides of mouse pancreatic tissues were also stained with hematoxylin and eosin (H&E) and Picro-sirius red stain kit (ScyTek Laboratories, Inc., Logan, UT, USA) for collagen staining, according to manufacturer instructions.

By light microscopy, the tissue sections of TMA were scored semiquantitatively for PRDM14 staining, as described previously [12]. Labeling scores were determined by multiplying the percentage of PRDM14-positive cells per slide (0–100%) by the dominant staining intensity (0 = negative, 1 = trace, 2 = weak, 3 = intermediate, and 4 = strong). Resulting scores ranged from 0 to 400.

In this study, we used reported data on PRDM14 staining scores in normal pancreas, PDAC, and cancer adjacent tissues using TMA [12] to compare the expression levels with that in PanIN and chronic pancreatitis.

Animals

Six-week-old female BALB/c mice were obtained from CLEA Japan, Inc. (Tokyo, Japan). Pancreatitis was induced referring to previous reports [4,17]. Chronic pancreatitis was induced by a single daily intraperitoneal injection of cerulein (0.1 mL of a 50 μg/mL-1 solution in saline, Bachem, Heidelberg, Germany) on five successive days. The pancreases were removed 3 days after the last cerulein injection. Acute pancreatitis was induced by 6-hourly injections of cerulein in 1 day, and the pancreases were removed at 24 h after the first cerulein injection. The pancreases were used for IHC. All animal experiments were performed in accordance with the guidelines for the care and use of laboratory animals of the University of Tokyo and were approved by the Institutional Animal Care and Use Committee of the University of Tokyo.

Cell culture

Two pancreatic cancer cell lines, PK-1 and AsPC-1 cells, were obtained and cultured as described previously [12]. The cells were identified by the cell banks using short tandem repeat analysis. All cell lines were incubated at 37 °C in a humidified atmosphere containing 5% CO2.

Cell treatment

Cells were incubated in culture medium in 6-well plates for 24 h and were then stimulated with cerulein (100 nM) or brefeldin A (17.8 μM; #9972, Cell Signaling Technology Inc., Beverly, MA, USA) and collected after 24 h.
Protein analysis by automated capillary electrophoresis, and immunodetection

Protein levels were quantified using an automated capillary electrophoresis and immunoassay system, Wes (ProteinSimple, CA, USA), as described previously [12]. We used the following primary antibodies: PRDM14 (ab187881) and 78-kDa glucose-regulated protein (GRP78; ab21685) from Abcam Inc., C/EBP homologous protein (CHOP; #2895), GAPDH (#5174), eukaryotic initiation factor 2 α-subunit (eIF2α; #5324), and phosphor-eIF2α (Ser51, #3398) from Cell Signaling Technology Inc. The specificity of the PRDM14 antibody was confirmed previously by western blotting using knockdown cells [12].

Analysis of SP cells

Isolation of SP cells was performed as described previously [12]. Briefly, cells in suspension were incubated with Hoechst 33342 dye (Sigma-Aldrich, St. Louis, MO, USA) with or without Reserpine (Sigma-Aldrich), a multidrug transporter inhibitor. The cells were stained with 7-amino actinomycin D (7-AAD) (BD Pharmingen, San Diego, CA, USA) and analyzed using a FACSAria flow cytometer (BD Biosciences, San Jose, CA, USA).

Results

PRDM14 expression in precursor of PDAC and chronic pancreatitis

We assessed PRDM14 expression in PanIN (grade 1–3), which is considered the most common precursor of PDAC, by IHC using TMA (Fig. 1). PRDM14-positive cells were detected in the PanIN structure. Although the PRDM14-positive cells were detected in the lesions surrounding strong PRDM14-positive PanIN, the periphery of PanIN lesions mostly showed no PRDM14 expression. Subsequently, we performed IHC using TMA of chronic pancreatitis, which is a risk factor of PDAC, and acute pancreatitis (Fig. 2A). PRDM14-positive cells were detected in chronic pancreatitis tissues overall. In contrast, acute pancreatitis tissues did not show PRDM14 expression. The tissues were also scored for staining semiquantitatively and compared with the staining scores of normal pancreatic tissue, PDAC, and cancer adjacent tissues, which we previously reported [12] (Fig. 2B). PRDM14 expression score did not significantly increase in PanIN compared to normal pancreatic tissue, because PRDM14-positive cells were few in the periphery. The staining score of chronic pancreatitis significantly increased to the level observed in PDAC and cancer adjacent tissues, while that of acute pancreatitis did not increase compared to normal tissue. The staining scores did not correlate with the PanIN grades (Table 1).

PRDM14 expression in pancreatitis mouse model

Chronic inflammation is considered to be related to tumorigenesis [4,7]. Moreover, the staining score for PRDM14 was as high in chronic pancreatitis as in PDAC. Therefore, we investigated the relationship between PRDM14 expression and chronic pancreatitis. To assess the relation between inflammation and PRDM14 expression, we used a mouse model of pancreatitis, which was induced upon intraperitoneal injection of cerulein. We prepared both chronic and acute pancreatitis to assess whether continuous inflammation is needed for increased PRDM14 expression (Fig. 3). The pancreas of chronic pancreatitis had higher fibrosis, which was confirmed by staining with Sirius red, than that of control and acute pancreatitis (Fig. 4A), as reported previously [4,17]. On IHC analysis, PRDM14-positive cells were observed in chronic pancreatitis models, but not in acute pancreatitis models and controls (Fig. 4A and B). These results suggested...
that chronic cerulein-induced inflammation increases PRDM14 expression in pancreas of normal mice.

PRDM14 expression in cerulein-stimulated pancreatic cancer cells

To assess the putative role of inflammation on PRDM14 expression in pancreatic cancer, pancreatic cancer cell lines, PK-1 and AsPC-1, were treated with cerulein. PRDM14 expression significantly increased upon cerulein treatment in both cell lines ($P < 0.05$) (Fig. 5). Additionally, endoplasmic reticulum (ER) stress is considered as one of the mechanisms of pancreatitis generation [18], and we previously reported that PRDM14 directly interacts with GRP78, which suggests a link between PRDM14 and ER stress [19]. Thus, we also assessed the effect of an ER stress inducer brefeldin A. Although brefeldin A induced ER stress- and unfolded protein response (UPR)-related downstream factors, GRP78, CHOP, and phosphorylated eIF2α, the drug did not increase PRDM14 expression (Fig. 5).

We have previously reported that PRDM14 regulates cancer stem-like phenotypes in pancreatic cancer cells [12]. Therefore, we assessed the number of SP cells, a cancer stem-like phenotype, in cerulein-treated cancer cell lines. SP cells very slightly increased in AsPC-1 cells ($P < 0.01$), but did not significantly change in PK-1 cells (Fig. 6).

Discussion

Pancreatic ductal adenocarcinoma is an aggressive and lethal disease, and screening tools for early-stage detection are needed. We previously found that PRDM14 was overexpressed in PDAC and cancer adjacent tissues, compared to normal pancreatic tissues, and regulates cancer phenotypes [12]. Therefore, in this report we assessed PRDM14 expression in precursor lesions of PDAC and chronic pancreatitis, which is a risk factor of the disease. PRDM14-positive cells were observed in both PanIN and chronic pancreatitis (Figs 1 and 2A). Interestingly, the staining score for PRDM14 in chronic pancreatitis was as elevated as that observed in PDAC and cancer adjacent tissues (Fig. 2B).

Recent studies have demonstrated that inflammation relates to various processes of tumor formation, including cancer initiation in early lesions, progression, and
Chronic inflammation, a repeat of injury and healing processes, is considered a trigger of tumorigenesis in several tissues [7,20]. In the pancreas, chronic pancreatitis is a risk factor of PDAC and is reported to initiate precursor lesions and assist the progression of such lesions to PDAC. Cerulein-induced chronic pancreatitis...
causes PanIN and invasive pancreatic cancer formation in KRAS-mutant mice, in which they are not formed by mutation alone [4,21]. Inflammatory responses induced by tumor-associated immune cells cause cancer cells to metastasize and migrate through the epithelial–mesenchymal transition [21,22]. Various inflammatory modulators, such as prostaglandin E2, have been shown to facilitate tumor progression, while anti-inflammatory agents have been found to inhibit tumor growth [23,24]. Furthermore, the relationship between inflammation and cancer stemness is also being gradually elucidated through the association between inflammation and cancer initiation, metastasis, and EMT. Prostaglandin E2 is also reported to enhance cancer stem-like phenotypes and increase proliferation of CSCs [25–27]. A cancer stem cell marker DcK1, which is also reported to be expressed in PanIN and facilitate tumor progression in KRAS-mutated mice and human pancreatic cancer, was upregulated by cerulein [28]. PRDM14 is known to relate to pluripotency in ES cells and to cancer stem-like properties in breast and pancreatic cancers [8,11,12]. In this study, PRDM14-positive cells were detected in PanIN and chronic pancreatitis (Figs 1 and 2A) in addition to PDAC tissues [12]. Moreover, chronic pancreatitis induced by cerulein increased PRDM14 expression in the pancreases of normal mice (Fig. 4). We have so far been unable to confirm whether PRDM14 expression is controlled at the transcriptional level and cannot exclude the possibility that the protein turnover is regulated. However, these findings support the participation of PRDM14 in chronic pancreatitis.

Fig. 5. PRDM14 expression in pancreatic cancer cell lines. Pancreatic cancer cell lines, PK-1 and AsPC-1, were treated with cerulein and ER stress inducer brefeldin A. Expression levels of PRDM14, GAPDH, GRP78, eIF2α, phospho-eIF2α, and CHOP in the cells were analyzed using Wes capillary electrophoresis system. GAPDH was used as a loading control. Expression levels of PRDM14 protein were normalized to that of GAPDH and plotted as fold changes relative to control. Error bars represent the mean ± SD of triplicate samples. Student’s t-test: **P < 0.01, *P < 0.05, ns, not significant.

Fig. 6. Side population cells in cerulein-treated PK-1 and AsPC-1 cells. SP cells in cerulein-treated PK-1 and AsPC-1 cells analyzed by flow cytometry using Hoechst 33342 dye. Reserpine, a multidrug transporter inhibitor, was used as a control for SP. Error bars in graphs represent mean ± SD of triplicate samples. Student’s t-test: **P < 0.01, ns, not significant.
of chronic inflammation in inducing cancer stemness prior to tumor progression. On the other hand, acute pancreatitis did not increase PRDM14 expression in normal pancreatic tissue (Fig. 4) indicating the important effect of chronic inflammation on cancer initiation and tumorigenesis.

Several mechanisms of pancreatitis generation have been identified, such as activation of nuclear factor-κB (NF-κB) [29], ER stress [18,30], and autophagy signaling in acinar cells [31]. Cerulein, which we used in this study, is considered to produce reactive oxygen species (ROS), which induce NF-κB and to activate inflammasomes, leading to inflammation [13,32]. Repeat injection of cerulein is also reported to induce chronic ER stress as well as chronic pancreatitis [18,32]. Previously, we reported the direct binding and cooperation of PRDM14 with GRP78, which is a heat-shock protein upregulated after ER stress, suggesting a relationship between ER stress and PRDM14 [19]. A single treatment with ER stress inducers, which increased GRP78, did not increase PRDM14 expression in pancreatic cancer cell lines (Fig. 5). On the other hand, cerulein treatment increased PRDM14 expression without increasing GRP78 expression. Although transfection of the binding partners did not also affect each protein’s expression [19], these results indicate that upregulation of PRDM14 expression by inflammation in pancreatic cancer cells required other pathways than ER stress.

We previously reported that inhibition of PRDM14 expression decreases cancer stem-like phenotypes, including SP cells, in pancreatic cancer cells [12]. Although cerulein increased PRDM14 expression in pancreatic cancer cell lines, it did not increase the number of SP cells (Figs 5 and 6). Because PRDM14 expression is already elevated, additional increase may have minimal effects. Furthermore, repeated cerulein treatment on successive days was needed to increase PRDM14 expression in the pancreas of normal mice, and 1-day treatment was not sufficient for increase (Fig. 4). However, single stimulation with cerulein was enough to increase PRDM14 expression in pancreatic cancer cell lines (Fig. 5). A normal pancreas may require repeated inflammation for induction of PRDM14 overexpression, while a single inflammation may be enough for already transformed pancreatic cancer cells. Although inflammation increased PRDM14 expression in PDAC cells without enhancing cancer stem-like phenotypes, inflammation may contribute to maintain the overexpression and tumor phenotypes in the cancer. Anti-inflammatory reagents have been reported to inhibit tumor growth and cancer stem-like phenotypes [23,25, 28,33]. PRDM14 expression may also be associated with anti-inflammatory effects on tumor phenotypes.

Our results revealed that cerulein-induced chronic pancreatitis increased PRDM14 expression in normal mice. Cerulein alone is not enough for tumorigenesis, and the combination with other factors is needed. For example, cerulein induces pancreatitis, but not PDAC, in mice without KRAS mutation, and induces pancreatitis, PanIN, and PDAC in mice with genetic KRAS mutations. To investigate the effects of PRDM14 expression induction by chronic pancreatitis on tumorigenesis, more experiments using transgenic mice, such as those harboring KRAS mutations and PRDM14 knockouts, should be performed in the future. If PRDM14 knockout reduces either inflammatory responses or the formation of PanIN and PDAC, targeting PRDM14 expression may be useful treatment strategy against the early lesions prior to PDAC.

PRDM14 is overexpressed in PDAC and regulates cancer stem-like phenotypes. In this study, we detected PRDM14-positive cells in PanIN and chronic pancreatitis. Using pancreatitis mouse models, we observed that cerulein-induced chronic inflammation on successive days increases PRDM14 expression in the pancreas of normal mice. Moreover, cerulein also increases PRDM14 expression in pancreatic cancer cells. Taken together, PRDM14 overexpression may be triggered by chronic pancreatitis prior to PDAC and regulate tumor initiation and progression.

Acknowledgements

This work was supported by grants from Japan Agency for Medical Research and Development (HT, KI), The Japanese Society of Gastroenterology (HT), Project Mirai Cancer Research Grants (HT), Pancreas Research Foundation of Japan (HT), and Sendai Kousei Hospital (HT).

Author contributions

CM and HT designed the experiments. CM performed the experiments, analyzed and interpreted data, and wrote the manuscript. KI supervised the research. All authors read and approved the manuscript.

Conflict of interest

The authors declare no conflict of interest.

References

1 Güngör C, Hofmann BT, Wolters-Eisfeld G and Bockhorn M (2014) Pancreatic cancer. Br J Pharmacol 171, 849–858.
2 Komatsu H, Tanji E, Sakata N, Aoki T, Motoi F, Naitoh T, Katayose Y, Egawa S, Unno M and Furukawa T (2014) A GNAS mutation found in pancreatic intraductal papillary mucinous neoplasms induces drastic alterations of gene expression profiles with upregulation of mucin genes. PLoS One 9, e87875.

3 Hosoda W, Sasaki E, Murakami Y, Yamao K, Shimizu Y and Yatabe Y (2015) GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas. Virchows Arch 466, 665–674.

4 Guerra C, Schuhmacher AJ, Cañamero M, Grippo PJ, Verdaguer L, Pérez-Galgelo L, Dubus P, Sandgren EP and Barbacid M (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11, 291–302.

5 Becker AE, Hernandez YG, Frucht H and Lucas AL (2014) Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol 20, 11182–11198.

6 Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludema G, Simeone DM, Zou W and Welling TH (2014) Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology 147, 1393–1404.

7 Taniguchi H, Moriya C, Igarashi H, Saitoh A, Yamamoto H, Adachi Y and Imai K (2016) Cancer stem cells in human gastrointestinal cancer. Cancer Sci 107, 1556–1562.

8 Tsuneyoshi N, Sumi T, Onda H, Nojima H, Nakatsuji N and Suemori H (2008) PRDM14 suppresses expression of differentiation marker genes in human embryonic stem cells. Biochem Biophys Res Commun 367, 899–905.

9 Nishikawa N, Toyoda M, Suzuki H, Honma T, FujikANE T, Ohmura T, Nishidate T, Ohe-Toyota M, Maruyama R, Sonoda T et al. (2007) Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Res 67, 9649–9657.

10 BiHX, Shi HB, Zhang T and Cui G (2015) PRDM14 promotes the migration of human non-small cell lung cancer through extracellular matrix degradation in vitro. Chin Med J (Engl) 128, 373–377.

11 Taniguchi H, Hoshino D, Moriya C, Zembutsu H, Nishiyama N, Yamamoto H, Kataoka K and Imai K (2017) Silencing PRDM14 expression by an innovative RNAi therapy inhibits stemness, tumorigenicity, and metastasis of breast cancer. Oncotarget 8, 46856–46874.

12 Moriya C, Taniguchi H, Miyata K, Nishiyama N, Kataoka K and Imai K (2017) Inhibition of PRDM14 expression in pancreatic cancer suppresses cancer stem-like properties and liver metastasis in mice. Carcinogenesis 38, 638–648.

13 Yu JH and Kim H (2012) Role of janus kinase/signal transducers and activators of transcription in the pathogenesis of pancreatitis and pancreatic cancer. Gut Liver 6, 417–422.

14 Jensen RT, Wank SA, Rowley WH, Sato S and Gardner JD (1989) Interaction of CCK with pancreatic acinar cells. Trends Pharmacol Sci 10, 418–423.

15 Sato S, Stark HA, Martinez J, Beaven MA, Jensen RT and Gardner JD (1989) Receptor occupation, calcium mobilization, and amylase release in pancreatic acini: effect of CCK-JMV-180. Am J Physiol 257, G202–G209.

16 Willemser S, Elsasser HP and Adler G (1992) Hormone-induced pancreatitis. Eur Surg Res 24 (Suppl 1), 29–39.

17 Steele CW, Karim SA, Foth M, Rishi L, Leach JD, Porter RJ, Nixon C, Jeffery Evans TR, Carter CR, Nibbs RJ et al. (2015) CXCR2 inhibition suppresses acute and chronic pancreatic inflammation. J Pathol 237, 85–97.

18 Sah RP, Garg SK, Dixit AK, Dudeja V, Dawra RK and Saluja AK (2014) Endoplasmic reticulum stress is chronically activated in chronic pancreatitis. J Biol Chem 289, 27551–27561.

19 Mori C, Taniguchi H, Nagatoishi S, Igarashi H, Tsumoto K and Imai K (2017) PRDM14 directly interacts with heat shock proteins HSP90alpha and glucose-regulated protein 78. Cancer Sci 109, 373–383.

20 Swidnicka-Siergiejko AK, Gomez-Chou SB, Cruz-Monserrate Z, Deng D, Liu Y, Huang H, Ji B, Azizian N, Daniuluk J, Lu W et al. (2017) Chronic inflammation initiates multiple forms of K-Ras-independent mouse pancreatic cancer in the absence of TP53. Oncogene 36, 3149–3158.

21 Hamada S, Masamune A and Shimosegawa T (2014) Inflammation and pancreatic cancer: disease promoter and new therapeutic target. J Gastroenterol 49, 605–617.

22 Shigdar S, Li Y, Bhattacharya S, O’Connor M, Pu C, Lin J, Wang T, Xiang D, Kong L, Wei MQ et al. (2014) Inflammation and cancer stem cells. Cancer Lett 345, 271–278.

23 Funahashi H, Satake M, Dawson D, Huynh NA, Reber HA, Hines OJ and Eibl G (2007) Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res 67, 7068–7071.

24 Takahashi M, Mutoh M, Ishigamori R, Fuji G and Imai T (2013) Involvement of inflammatory factors in pancreatic carcinogenesis and preventive effects of anti-inflammatory agents. Semin Immunopathol 35, 203–227.

25 Pang LY, Hurst EA and Argyle DJ (2016) Cyclooxygenase-2: A role in cancer stem cell survival and repopulation of cancer cells during therapy. Stem Cells Int 2016, 2048731.
26 Wang D, Fu L, Sun H, Guo L and DuBois RN (2015) Prostaglandin E2 promotes colorectal cancer stem cell expansion and metastasis in mice. *Gastroenterology* **149** (1884–1895), e4.
27 Li HJ, Reinhardt F, Herschman HR and Weinberg RA (2012) Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. *Cancer Discov* **2**, 840–855.
28 Mohammed A, Janakiram NB, Madka V, Brewer M, Ritchie RL, Lightfoot S, Kumar G, Sadeghi M, Patlolla JM, Yamada HY et al. (2015) Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression. *Oncotarget* **6**, 15524–15539.
29 Chen X, Ji B, Han B, Ernst SA, Simeone D and Logsdon CD (2002) NF-kappaB activation in pancreas induces pancreatic and systemic inflammatory response. *Gastroenterology* **122**, 448–457.
30 Garg AD, Kaczmarek A, Krysko O, Vandenabeele P, Krysko DV and Agostinis P (2012) ER stress-induced inflammation: does it aid or impede disease progression? *Trends Mol Med* **18**, 589–598.
31 Mareninova OA, Hermann K, French SW, O’Konski MS, Pandol SJ, Webster P, Erickson AH, Katunuma N, Gorelick FS, Gukovsky I et al. (2009) Impaired autophagic flux mediates acinar cell vacuole formation and trypsinogen activation in rodent models of acute pancreatitis. *J Clin Invest* **119**, 3340–3355.
32 Kanak MA, Shahbazov R, Yoshimatsu G, Levy MF, Lawrence MC and Naziruddin B (2017) A small molecule inhibitor of NFkappaB blocks ER stress and the NLRP3 inflammasome and prevents progression of pancreatitis. *J Gastroenterol* **52**, 352–365.
33 Moon CM, Kwon JH, Kim JS, Oh SH, Jin Lee K, Park JJ, Pil Hong S, Cheon JH, Kim TI and Kim WH (2014) Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer. *Int J Cancer* **134**, 519–529.